Shares of ResMed have gained 6.6% over the past four weeks to close at $194.88, but Wall Street analysts' short-term price targets suggest a potential upside of 28.2%. The mean estimate of $249.86 is based on 14 price targets ranging from $180.00 to $321.00, with a standard deviation of $42.83. Analysts have also grown more optimistic about the company's earnings prospects, with the Zacks Consensus Estimate for the current year increasing as one estimate moved higher with no negative revisions. ResMed currently holds a Zacks Rank of 2, or Buy, placing it in the top 20% of over 4,000 ranked stocks. While price targets should be treated with skepticism, the direction of price movement implied by the consensus target appears to be a good guide.
ResMed IncWall Street analysts' price targets suggest 28.2% upside and earnings estimates are rising.